CR9322A - Metodos para control del intervalo qt - Google Patents
Metodos para control del intervalo qtInfo
- Publication number
- CR9322A CR9322A CR9322A CR9322A CR9322A CR 9322 A CR9322 A CR 9322A CR 9322 A CR9322 A CR 9322A CR 9322 A CR9322 A CR 9322A CR 9322 A CR9322 A CR 9322A
- Authority
- CR
- Costa Rica
- Prior art keywords
- control methods
- interval control
- subject
- formula
- group
- Prior art date
Links
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 210000001308 heart ventricle Anatomy 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 230000028161 membrane depolarization Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002336 repolarization Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Esta invencion se relaciona con metodos para controlar la duracion de la despolarizacion y repolarizacion del ventriculo cardiaco y por lo tanto del intervalo QT, de manera terapeuticamente utiles en un sujeto, que comprende administrar al sujeto en necesidad del mismo una cantidad terapeuticamente eficaz de un compuesto que se selecciona del grupo que consiste de la formula (I) y la formula (II) o una sal o ester farmaceuticamente aceptable del mismo; en donde fenilo esta sustituido en X con uno a cinco atomos de halogeno que se seleccionan del grupo que consiste de fluor, cloro, bromo y yodo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64544705P | 2005-01-20 | 2005-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR9322A true CR9322A (es) | 2008-09-09 |
Family
ID=36147919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR9322A CR9322A (es) | 2005-01-20 | 2007-08-17 | Metodos para control del intervalo qt |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7846968B2 (es) |
| EP (1) | EP1850841A1 (es) |
| JP (1) | JP2008528489A (es) |
| KR (1) | KR20080025034A (es) |
| CN (1) | CN101146527A (es) |
| AR (1) | AR052885A1 (es) |
| AU (1) | AU2006206778A1 (es) |
| BR (1) | BRPI0606484A2 (es) |
| CA (1) | CA2595599A1 (es) |
| CR (1) | CR9322A (es) |
| EA (1) | EA200701536A1 (es) |
| IL (1) | IL184730A0 (es) |
| MX (1) | MX2007008845A (es) |
| NO (1) | NO20074175L (es) |
| NZ (1) | NZ556497A (es) |
| TW (1) | TW200637540A (es) |
| WO (1) | WO2006078524A1 (es) |
| ZA (1) | ZA200706916B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4719890B2 (ja) * | 2006-11-09 | 2011-07-06 | 国立大学法人三重大学 | トルサード・ド・ポアンツ型心室頻拍を呈するゼブラフィッシュ |
| CZ2007376A3 (cs) * | 2007-05-30 | 2008-12-10 | Ústav prístrojové techniky AV CR, v.v.i. | Zpusob analýzy ventrikulární repolarizace |
| WO2009034507A2 (en) * | 2007-09-12 | 2009-03-19 | Koninklijke Philips Electronics, N.V. | Qt interval monitoring system with alarms and trending |
| US8019406B2 (en) * | 2008-03-10 | 2011-09-13 | Biotronik Crm Patent Ag | Apparatus and method to assess the risk of R-on-T event |
| FR2953410B1 (fr) * | 2009-12-09 | 2012-02-24 | Univ Claude Bernard Lyon | Compositions antivirales pharmaceutiques ou veterinaires |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| JP6954582B2 (ja) * | 2016-12-22 | 2021-10-27 | 国立大学法人滋賀医科大学 | 医薬組成物 |
| US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US12396970B2 (en) | 2021-08-20 | 2025-08-26 | AltaThera Pharmaceuticals LLC | Anti-arrhythmic compositions and methods |
| US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
| US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
| US12117453B2 (en) | 2018-12-07 | 2024-10-15 | Washington University | Predicting patient response to sodium channel blockers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3265728A (en) | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5698588A (en) | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| AU7349301A (en) * | 2000-07-21 | 2002-02-05 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| ES2262826T3 (es) * | 2001-02-27 | 2006-12-01 | Ortho-Mcneil Pharmaceutical, Inc. | Uso de un compuesto de carbamato en la prevencion o el tratamiento de transtornos de ansiedad. |
-
2006
- 2006-01-11 EP EP06718114A patent/EP1850841A1/en not_active Withdrawn
- 2006-01-11 EA EA200701536A patent/EA200701536A1/ru unknown
- 2006-01-11 NZ NZ556497A patent/NZ556497A/en not_active IP Right Cessation
- 2006-01-11 JP JP2007552172A patent/JP2008528489A/ja active Pending
- 2006-01-11 CN CNA2006800089860A patent/CN101146527A/zh active Pending
- 2006-01-11 AU AU2006206778A patent/AU2006206778A1/en not_active Abandoned
- 2006-01-11 WO PCT/US2006/001000 patent/WO2006078524A1/en not_active Ceased
- 2006-01-11 KR KR1020077018992A patent/KR20080025034A/ko not_active Ceased
- 2006-01-11 US US11/329,757 patent/US7846968B2/en not_active Expired - Fee Related
- 2006-01-11 BR BRPI0606484-1A patent/BRPI0606484A2/pt not_active IP Right Cessation
- 2006-01-11 CA CA002595599A patent/CA2595599A1/en not_active Abandoned
- 2006-01-11 MX MX2007008845A patent/MX2007008845A/es unknown
- 2006-01-19 TW TW095101996A patent/TW200637540A/zh unknown
- 2006-01-20 AR ARP060100224A patent/AR052885A1/es not_active Application Discontinuation
-
2007
- 2007-07-19 IL IL184730A patent/IL184730A0/en unknown
- 2007-08-14 NO NO20074175A patent/NO20074175L/no not_active Application Discontinuation
- 2007-08-17 CR CR9322A patent/CR9322A/es not_active Application Discontinuation
- 2007-08-17 ZA ZA200706916A patent/ZA200706916B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101146527A (zh) | 2008-03-19 |
| IL184730A0 (en) | 2008-08-07 |
| KR20080025034A (ko) | 2008-03-19 |
| EP1850841A1 (en) | 2007-11-07 |
| EA200701536A1 (ru) | 2008-02-28 |
| BRPI0606484A2 (pt) | 2009-06-30 |
| AR052885A1 (es) | 2007-04-11 |
| TW200637540A (en) | 2006-11-01 |
| ZA200706916B (en) | 2009-04-29 |
| AU2006206778A1 (en) | 2006-07-27 |
| WO2006078524A1 (en) | 2006-07-27 |
| NZ556497A (en) | 2011-03-31 |
| US7846968B2 (en) | 2010-12-07 |
| CA2595599A1 (en) | 2006-07-27 |
| US20070010578A1 (en) | 2007-01-11 |
| MX2007008845A (es) | 2007-11-08 |
| JP2008528489A (ja) | 2008-07-31 |
| NO20074175L (no) | 2007-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR9322A (es) | Metodos para control del intervalo qt | |
| ECSP088179A (es) | Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos | |
| PE20201146A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| ECSP088172A (es) | Metodos para tratar la epileptogenesis | |
| AR062980A1 (es) | Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida | |
| TW200612911A (en) | Compounds for the treatment of inflammatory disorders | |
| CY1111363T1 (el) | Τρικυκλικος ανταγωνιστης υποδοχεων θρομβινης | |
| GT200600055A (es) | Combinación de compuestos organicos | |
| TW200616620A (en) | Compounds for the treatment of inflammatory disorders | |
| IL311873A (en) | Combination therapy for treating malignancies | |
| CY1114266T1 (el) | Ανταγωνιστης υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες | |
| EP3915566A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE, CONTAINING TAURODEOXYCHOLIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS THE ACTIVE INGREDIENT | |
| ECSP11011030A (es) | Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional. | |
| MA32785B1 (fr) | Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine | |
| NO20072934L (no) | Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt | |
| TNSN07447A1 (en) | Treatment of liver diseases in which iron plays a role in pathogenesis | |
| AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
| DK2078022T3 (da) | Spirobenzazepiner anvendt som vasopressinantagonister | |
| CO6190539A2 (es) | Composiciones de carbamato fenilalquilo | |
| PA8467401A1 (es) | Procedimiento para tratar la insuficiencia cardiaca | |
| PE20230680A1 (es) | Inhibidores de il4i1 y metodos de uso | |
| ECSP077395A (es) | Compuesto de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos | |
| NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
| GT200600160A (es) | Tratamiento del dolor | |
| CR7854A (es) | Dihidrofenantridinosulfonamidas sustituidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |